We found that SCFA treatment, especially butyrate, resulted in lowering the levels of urine ACR (Figure 2(a)) and in lowering serum urea (Figure 2(b)), creatinine (Figure 2(c)), and cystatin C (Figure 2(d)) levels, markers of the severity of renal dysfunction in DN. This evidence concerns the gene CST3 and liver dysplastic nodule.